Abstract
Although the definition of benign multiple sclerosis (BMS) remains controversial, it is generally applied to a subgroup of MS patients showing little disease progression, with minimal disability decades after disease onset, and is based mainly on changes in motor function. Recent studies, however, reveal that deterioration of cognitive function, fatigue, pain, and depression also occur in BMS patients, causing negative impact on work and social activities, despite complete preservation of motor function. Using conventional MRI techniques, lesion load observed in BMS is similar to levels in other disease subtypes; however, newer quantitative MRI techniques show less tissue damage, as well as greater repair and compensatory efficiency following MS injury. Currently accepted criteria for BMS diagnosis may cause overestimation of true prevalence, underscoring the need for routine monitoring of nonmotor symptoms and imaging studies. Clearly, the definition of BMS currently applied in clinical practice requires reassessment.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Lublin F, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907–11.
Confavreux C, Vukusic S, Adeleine S. Early clinical predictors of progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126:770–82.
Confavreux C, Vukusic S, Morau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430–8.
Eriksson M, Andersen O, Rummarker B. Long-term follow-up of patients with clinically isolated syndromes, relapsing remitting and secondary progressive multiple sclerosis. Mult Scler. 2003;9:260–74.
Rummarker B, Andersen O. Prognostic factors in multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993;116:117–34.
Pittock S, Mayr W, McClelland R, et al. Disability profile of MS did not change over 10 years in population-based prevalence cohort. Neurology. 2004;62:601–6.
Pittock S, Mayr W, McClelland R, et al. Change in MS-related disability in a population-based cohort: a 10 year follow-up study. Neurology. 2004;62:51–9.
Rodriguez M, Siva A, Cross S, et al. Impairment, disability, and handicap in multiple sclerosis: a population based study in Olmsted County, Minnesota. Neurology. 1994;44:28–33.
Weinshenker B, Bass B, Rice G. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain. 1989;112:133–46.
Weinshenker B, Rice G, Noseworthy J, et al. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of aoutcome. Brain. 1991;114:1045–56.
Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology. 2005;66:172–7.
Cohen JA, Rudick R. Multiple sclerosis therapeutics. 4th ed. New York: Cambridge University Press; 2011.
Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169–78.
Comi G. Clinically isolated syndrome: the rationale for early treatment. Nat Clin Pract Neurol. 2008;4:234–5.
McAlpine D. The benign form of multiple sclerosis: results of long-term study. BMJ. 1964;2:1029–32.
Thomson AJ, Hutchinson M, Brazil J, et al. A clinical and laboratory study of benign multiple sclerosis. Q J Med. 1986;58:69–80.
Hawkins SA, McDonell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry. 1999;67:148–52.
Costelloe L, Thompson A, Walsh C, et al. Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Psychiatry. 2008;79:1245–8.
• Ramsarransing GSM, De Keyser J. Benign course in multiple sclerosis: a review. Acta Neurol Scand. 2006;113:359–69. This article review different aspects of BMS, providing information regarding development of new definitions, prognostic factors, neuroimaging, and patophysiology of the disease..
Glad S, Nyland H, Myhr KM. Benign multiple sclerosis. Acta Neurol Scand. 2006;183:55–7.
Sayao AL, Devonshire V, Tremlett H. Longitudinal follow-up of “benign” multiple sclerosis at 20 years. Neurology. 2007;68:496–500.
Patti F, Russo P, Pappalardo A, et al. Predictors of quality of life among patients with multiple sclerosis: an Italian cross-sectional study. J Neurol Sci. 2007;252:121–9.
Lauer K, Firnhaber W. Epidemiological investigations into multiple sclerosis in Southern Hesse: V. Course and prognosis. Acta Neurol Scand. 1987;76:12–7.
Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20 year population-based follow-up study. Ann Neurol. 2004;56:303–6.
Benedikz J, Steffansson M, Guomundsson J, et al. The natural history of untreated multiple sclerosis in Iceland: A total based population-based 50 years prospective study. Clin Neurol Neurosurg. 2002;104:208–10.
Poser S, Wikstrom J, Bauer HJ. Clinical data and the identification of special forms of multiple sclerosis in 1271 cases studied with standardized documentation system. J Neurol Sci. 1979;40:159–68.
Glad SB, Aarseth JH, Nyland H, Riise T, Myhr KM. Benign multiple sclerosis: a need for a consensus. Acta Neurol Scand. 2010;122 Suppl 190:44–50.
Rudge P. The value of natural history studies of multiple sclerosis. Brain. 1999;122:591–2.
Dawson DM. Benign multiple sclerosis: some recent ideas. Curr Neurol Neurosci Rep. 2008;8:1–4.
Engell T. A clinical patho-anatomical study of clinically silent multiple sclerosis. Acta Neurol Scand. 1989;79:428–30.
Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227–31.
Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. 1989;112:1419–28.
Fog T, Linnemann F. The course of multiple sclerosis in 73 cases with computer-designed curves. Acta Neurol Scand. 1970;47(Suppl):3–175.
Patzold U, Pocklington P. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976 to 1980. Acta Neurol Scand. 1982;65:248–66.
Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain. 1990;113:1597–628.
Ramsaransing G, Mauritis N, Zwanikken C, De Keyser J. Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review. Mult Scler. 2001;7:345–7.
Glad SB, Nyland HI, Aarset JH, Riise T, Myhr KM. Long-term follow-up of benign multiple sclerosis in Horland County, Western Norway. Mult Scler. 2009;15:942–50.
Midgard R, Albrektsen G, Riise T, et al. Prognostic factors for survival in multiple sclerosis: a longitudinal population based study in More and Romsdal, Norway. J Neurol Neurosurg Psychiatry. 1995;58:417–21.
Kurtzke JF, Beebe GW, Nagler B, et al. Studies on the natural history of multiple sclerosis: 8. Early prognostic features of the alter course of the illness. J Chronic Dis. 1977;30:819–30.
Leibowitz U, Alter M. Clinical factors associated with increased disability in multiple sclerosis. Acta Neurol Scand. 1970;46:53–70.
McAlpine D. The benign form of multiple sclerosis: a study based on 241 cases seen in three years of onset and followed up until the tenth year or more of the disease. Brain. 1961;84:186–203.
Ramsaransing GSM, De Keyser J. Predictive value of clinical characteristics for “benign” multiple sclerosis. Eur J Neurol. 2007;14:885–9.
Sayao AL, Bueno AM, Devonshire V, et al. The psychosocial and cognitive impact of longstanding “benign” multiple sclerosis. Mult Scler J. 2011;17:1375–83.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability sattus scale (EDSS). Neurology. 1983;33:1444–52.
Correale J, Peirano I, Romano L. Benign multiple sclerosis: a new definition of this entity is needed. Mult Scler J. 2012;18:210–8.
Chiavalloti N, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Nerol. 2008;7:1139–51.
•• Amato MP, Zipoli V, Goretti B, et al. Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol. 2006;253:1054–9. A seminal article describing cognitive impairment in BMS patients, as well as worsening of fatigue and depression, with negative impact on work and social activities. The article suggests that current BMS definition may overestimate incidence of the pathology..
Portaccio E, Stromillo ML, Goretti B, et al. Neuropsychological and MRI measures predict-short term evolution in benign multiple sclerosis. Neurology. 2009;73:498–503.
Trisolini M, Honeycutt A, Wiener J, Lesesne S. Global economy impact of multiple sclerosis. http://www.msif.org/document.rm?id=651. Accessed March 2012.
Glad SB, Nyland H, Aarset JH, et al. How long can you keep working with benign multiple sclerosis? J Neurol Neurosurg Psychiatry. 2011;82:78–82.
Rao SM, Leo GJ, Ellington L, et al. Cognitive dysfunction in multiple sclerosis: II. Impact on employment and social functioning. Neurology. 1991;41:692–6.
Smith MM, Arnett PA. Factors related to employment status changes in individuals with multiple sclerosis. Mult Scler. 2005;11:602–9.
•• Rovaris M, Barkhof F, Calabrese M, et al. MRI features of benign multiple sclerosis: towards a definition of this disease subtype. Neurology. 2009;72:1693–701. This article, based on MRI studies, reviewed potential mechanisms to explain the BMS course. The authors suggested, as possible explanations for their findings, (1) paucity of tissue damage within and outside lesions, (2) sparing of clinically eloquent regions, and (3) presence of effective compensatory mechanisms..
Koopmans RA, Li DK, Grochowski E, et al. Benign versus chronic progressive multiple sclerosis: magnetic resonance imaging features. Ann Neurol. 1989;25:74–81.
Filippi M, Capra R, Campi A, et al. Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996;60:526–30.
Thompson AJ, Kermode AG, MacManus DG, et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ. 1990;300:631–4.
Strasser-Fuchs S, Enzinger C, Ropele S, et al. Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox? Mult Scler. 2008;14:205–11.
Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131:808–17.
Rocca MA, Colombo B, Falini A, et al. Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol. 2005;4:618–26.
Rocca MA, Ceccarelli A, Rodegher M, et al. Preserved brain adaptive properties in patients with benign multiple sclerosis. Neurology. 2010;74:142–9.
Filippi M, Iannucci G, Tortorella C, et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology. 1999;52:588–94.
DeStefano N, Battaglini M, Stromillo ML, et al. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain. 2006;129:2008–16.
Amato MP, Portaccio E, Stromillo ML, et al. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology. 2008;71:632–8.
Benedetti B, Rovaris M, Rocca MA, et al. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Mult Scler. 2009;15:789–94.
Gauthier SA, Berger AM, Liptak Z, et al. Rates of brain atrophy in benign vs early multiple sclerosis. Arch Neurol. 2009;66:234–7.
Brass SD, Narayanan S, Antel JP, et al. Axonal damage in multiple sclerosis patients with high versus low disability. Can J Neurol Sci. 2004;31:225–8.
Benedetti B, Rovaris M, Rocca M, et al. Neuroaxonal brain viability does not differ between benign and relapsing-remitting MS patients. Neurol Sci. 2008;29(Suppl):S196.
• Mesaros S, Rovaris M, Pagani E, et al. A magnetic resonance imaging voxel-based morphometry study of regional gray matter atrophy in patients with benign multiple sclerosis. Arch Neurol. 2008;65:1223–30. This article proposed cerebellar gray matter atrophy as a major determinant of irreversible locomotor disability in MS, with absence of this finding in BMS possibly explaining the favorable disease course..
Ceccareli A, Filippi M, Neema M, et al. T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis. Mult Scler. 2009;15:678–86.
Calabrese M, Filippi M, Rovaris M, et al. Evidence of relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. Mult Scler. 2009;15:36–41.
Feinstein A. The clinical neuropsychiatry of multiple sclerosis. Cambridge: Cambridge University Press; 1999.
Lin X, Biumhardt L, Constanstinescu C. The relationship of brain and spinal cord volume to disability in clinical subtypes of multiple sclerosis: a three dimensional MRI study. Acta Neurol Scand. 2003;108:401–6.
Lycklama à Nijeholt GJ, van Walderveen MA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain. 1998;121:687–97.
Benedetti B, Rocca MA, Rovaris M, et al. A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2010;81:26–30.
Filippi M, Campi A, Colombo B, et al. Spinal cord MRI study of benign and secondary progressive multiple sclerosis. J Neurol. 1996;243:502–5.
Giorgio A, Portaccio E, Stromillo ML, et al. Cortical functional reorganization and its relationship with brain structural damage in patients with benign multiple sclerosis. Mult Scler. 2010;16:1326–34.
Rocca MA, Valsasina P, Cecarelli A, et al. Structural and functional MRI correlates of Stroop control in benign MS. Hum Brain Mapp. 2009;30:276–90.
Penner IK, Rausch M, Kappos L, et al. Analysis of impairment related functional architecture in MS patients during performance of different attention task. J Neurol. 2003;250:461–72.
Pollman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revision of the McDonald criteria. Ann Neurol. 2011;69:292–302.
Swanton JK, Rovira A, Tintore M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol. 2007;6:677–86.
Guttman CR. Simplified MRI prediction of clinically definite multiple sclerosis: a stepping stone towards treatment criteria. Nat Clin Pract Neurol. 2008;4:136–7.
McAlpine D. The benign form of multiple sclerosis: a study based on 241 cases seen within three years of onset and followed up until the tenth year of the disease. Brain. 1961;84:186–203.
Riser M, Géraud J, Rascol A, et al. L’evolution de la sclérose en palques étude de 203 observations suivies au-delá de 10 ans. Rev Neurol Paris. 1971;124:479–86.
Shepered DI. Clinical features of multiple sclerosis in north-east Scotland. Acta Neurol Scand. 1979;60:218–30.
Amato MP, Ponziani G, Bartolozzi ML, Siracusa G. A prospective study on the natural history of multiple sclerosis clues to the conduct and interpretation of clinical trials. J Neurol Sci. 1999;168:96–106.
Poser S, Raun NE, Poser W. Age at onset, initial symptomatology and the course of multiple sclerosis. Acta Neurol Scand. 1982;66:355–62.
Hutchinson M. Disability due to multiple sclerosis: a community-based study of an Irish county. Irish Med J. 1986;79:48–50.
McDonell GV, Hawkins SA. An epidemiologic study of multiple sclerosis in Northern Island. Neurology. 1998;50:423–8.
Cabre P, Heinzlef O, Merle H, et al. MS and neuromyelitis óptica in Martinique (French and West Indies). Neurology. 2011;56:507–14.
Krisztina B, Rajda C, Füvesi J, et al. The prevalence of MS distribution of clinical forms of the disease and functional status of patients in Csóngrad County, Hungary. Eur Neurol. 2011;46:206–9.
Perini P, Tagliaferri C, Belloni M, et al. The HLA-DR13 haplotype associated with “benign” multiple sclerosis in northeast Italy. Neurology. 2001;57:158–9.
Kalanie H, Ghaagozli K, Kalanie AR. Multiple sclerosis: report of 200 cases from Iran. Mult Scler. 2003;9:36–8.
Hirst C, Ingram G, Swingler, et al. Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis. J Neurol Neurosurg Psychiatry. 2008;79:1137–43.
Disclosure
J. Correale: Merck Serono Argentina Advisory Board, Biogen-Idec LATAm Advisory Board, Novartis Argentina Advisory Board, and speakers’ bureaus (Merck-Serono Argentina, Teva Tuteur Argentina, Biogen-Idec Argentina, Biogen Idec LATAM); M. C Ysrraelit: none; M. P. Fiol: Merck Serono (consultant).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Correale, J., Ysrraelit, M.C. & Fiol, M.P. Benign Multiple Sclerosis: Does it exist?. Curr Neurol Neurosci Rep 12, 601–609 (2012). https://doi.org/10.1007/s11910-012-0292-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11910-012-0292-5